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Abstract
Background: The RTOG 94-13 trial has provided evidence that patients with high risk prostate
cancer benefit from an additional radiotherapy to the pelvic nodes combined with concomitant
hormonal ablation. Since lymphatic drainage of the prostate is highly variable, the optimal target
volume definition for the pelvic lymph nodes is problematic. To overcome this limitation, we tested
the feasibility of an intensity modulated radiation therapy (IMRT) protocol, taking under
consideration the individual pelvic sentinel node drainage pattern by SPECT functional imaging.
Methods:  Patients with high risk prostate cancer were included. Sentinel nodes (SN) were
localised 1.5–3 hours after injection of 250 MBq 99mTc-Nanocoll using a double-headed gamma
camera with an integrated X-Ray device. All sentinel node localisations were included into the
pelvic clinical target volume (CTV). Dose prescriptions were 50.4 Gy (5 × 1.8 Gy / week) to the
pelvis and 70.0 Gy (5 × 2.0 Gy / week) to the prostate including the base of seminal vesicles or
whole seminal vesicles. Patients were treated with IMRT. Furthermore a theoretical comparison
between IMRT and a three-dimensional conformal technique was performed.
Results: Since 08/2003 6 patients were treated with this protocol. All patients had detectable
sentinel lymph nodes (total 29). 4 of 6 patients showed sentinel node localisations (total 10), that
would not have been treated adequately with CT-based planning ('geographical miss') only. The
most common localisation for a probable geographical miss was the perirectal area. The
comparison between dose-volume-histograms of IMRT- and conventional CT-planning
demonstrated clear superiority of IMRT when all sentinel lymph nodes were included. IMRT
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allowed a significantly better sparing of normal tissue and reduced volumes of small bowel, large
bowel and rectum irradiated with critical doses. No gastrointestinal or genitourinary acute toxicity
Grade 3 or 4 (RTOG) occurred.
Conclusion:  IMRT based on sentinel lymph node identification is feasible and reduces the
probability of a geographical miss. Furthermore, IMRT allows a pronounced sparing of normal
tissue irradiation. Thus, the chosen approach will help to increase the curative potential of
radiotherapy in high risk prostate cancer patients.
Background
Treatment strategies for localised prostate cancer have to
address issues of local control, prevention of distant
spread and treatment of microscopic locoregional spread.
It has been shown that local control is critically interre-
lated with the prevention of distant spread, since late
metastases occur in patients with local failure [1]. In order
to increase the efficacy of radiotherapy, many recent trials
suggest the strategy of dose escalation [2-19].
Particularly the availability of three-dimensional confor-
mal radiation treatment (3D-CRT) and further develop-
ment of intensity modulated radiation treatment (IMRT)
allow the application of higher radiation doses to the
prostate without increased toxicities to normal tissues.
The available data suggest that prostate cancer especially
in patients with intermediate risk profile benefit from
dose escalation (reviewed in [20]). On the other hand,
patients with a high risk profile do not show such a steep
dose response relationship because of the risks of loco-
regional and ultimately systemic spread.
A further approach to increase local control rates and the
rates of biochemical disease control is the combination of
radiation with anti-hormonal treatment. Several recently
published results of larger trials [21-23] could demon-
strate a clear benefit from a combined treatment in
patients with locally advanced prostate cancer. Most of
these trials have employed radiation portals covering the
locoregional lymphatic drainage in addition to the pros-
tate using a standardised anatomical definition.
Of special importance in this regard is the four-armed
RTOG 94-13 trial comparing neoadjuvant vs. adjuvant
anti-hormonal treatment and radiotherapy of the whole
pelvis vs. the prostate only. Patients with an estimated risk
of pelvic lymph node involvement > 15% had a signifi-
cant benefit when treated with neoadjuvant and concur-
rent hormonal ablation in combination with
radiotherapy to the prostate (70.2 Gy) and the pelvic
lymph nodes (50.4 Gy). The most significant difference in
4-year progression free survival rates was observed
between the groups of whole pelvis (61%) and prostate
only (45%) irradiated patients when treated with neoad-
juvant and concurrent hormonal ablation [23].
Thus, besides dose escalation strategies or combination
with anti-hormonal treatments, adjuvant coverage of the
pelvic lymph nodes may be of importance for an opti-
mised tumour control.
Currently, the definition of an adjuvant pelvic target vol-
ume is derived from non-individualised anatomical lym-
phatic drainage patterns. Radiation planning and therapy
is mostly performed as 3D-CT based treatment along the
ICRU 50 guidelines.
However, the lymphatic drainage from the prostate is
highly variable. In this regard, data on sentinel lymph
nodes analysis in prostate cancer are of key importance.
To optimise lymphadenectomy techniques, Wawroschek
et al. [24,25] and Weckermann et al. [26] tested the senti-
nel lymph node (SN) identification with prostate lym-
phoscintigraphy and radio-guided surgery in large cohort.
The results demonstrated that sentinel node identification
in prostate cancer is feasible with a sensitivity between 93
and 96% and enables higher detection rates of microme-
tastases. However, the authors noted a strong individual
variability of the lymphatic drainage in their patient
cohort. Interestingly, only 44.2% of detectable cases with
positive nodes were found in the obturator fossa, the most
common area for a limited lymphadenectomy. These
findings correspond to surgical data of 103 patients after
extended lymphadenectomy [27]. In the latter, the most
common areas of lymph node metastases were the exter-
nal and internal iliac, followed by obturator, common
iliac and presacral regions.
Considering these results, the definition of standardised
target volumes covering the pelvic lymph nodes is associ-
ated with several problems. Trying to cover all possible
areas of lymphatic drainage increases the probability of
toxicities. In contrast, by limiting the target volume to the
most commonly involved lymph node areas increases the
risk of incomplete target volume coverage.
To overcome the limitations described above, we started
an IMRT trial for high risk prostate cancer with a target
volume definition based on the average distribution of
positive lymph nodes in prostate cancer patients comple-
mented by sentinel node functional imaging with SPECT.BMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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Methods
Patients
Patients with histologically proven high risk prostate can-
cer, but cN0 cM0 stage, were included after providing
informed consent. High risk profile was defined as T3 or
T4 stage (all) or PSA > 20 ng/mL (all) or PSA 10 – 20 ng/
mL with Gleason Scores = 7. Besides PSA level, rectal-dig-
ital examination and biopsy, the pre-therapeutic staging
included a computed tomographic and/or magnetic reso-
nance imaging of the abdomen and pelvis, an ultrasound
of the prostate, a total body bone scan and X-ray of the
chest. The clinical TNM stage was determined based on
these staging results.
Localisation of sentinel nodes
To permit a 3D-localisation of the sentinel nodes, trans-
mission and emission scans were acquired using a double-
headed gamma camera with an integrated X-Ray device
(Millennium VG & Hawkeye®, GE Medical Systems
Europe, Buc Cedex, France) 1.5–3 hours after transrectal
intraprostatic injection of 250 MBq 99mTc-Nanocoll. A sin-
gle ultrasound-guided central application was performed
per prostate lobe. After the anatomical-functional image
fusion, the scans were analysed with respect to 3D-locali-
sation and number of sentinel nodes. The sentinel nodes
were three-dimensionally located by an experienced
member of the nuclear medicine department (K.E., R.B.).
For a systematic topographic evaluation of lymph node
localisation, we used the Cross-sectional Nodal Atlas pub-
lished by Martinez-Monge 1999 [28](figure 1).
Treatment planning
Intensity modulated radiotherapy planning was based on
three CT scans of the pelvis in supine (2 patients) and
prone (4 patients, using a belly board) position at 3 mm
slice spacing from two cm below the ischeal tuberosities
to the L 4/5 interspace. For a comfortable bladder filling,
patients were instructed to avoid urination during the last
45 minutes before the procedure. The CT datasets were
transferred to the Pinnacle® treatment planning system
(Philips Medical Systems, DA Best, Netherlands) for seg-
mentation. Clinical target volume (CTV) and organs at
risk (OAR) were outlined in each CT image. OAR included
rectum, colon/sigmoid, small bowel, bladder and hips.
Image fusion was done by adjusting the bone structures of
the pelvis. Finally, a single enclosing contour was derived
from the three outlined CTV/OAR. For the resulting plan-
ning target volume (PTV) the enclosing CTV contour was
expanded with a 3D safety margin of 7 mm.
Since two different risk areas are treated simultaneously,
the term first- and second-order CTV will be used in the
following. The first-order CTV included the prostate and
the base of seminal vesicles. In cases of T stage ≥ 3 or an
estimated risk for an involvement of the seminal vesicles
> 15% (Partin nomograms) [29], seminal vesicles were
included into the boost volume.
The second-order CTV included the first order CTV and
routinely the obturator and hypogastric lymph nodes (fol-
lowing the nomenclature introduced by Martinez-Monge:
Periprostatic and seminal vesicle lymphatic plexus, the
parts of the perivesical and the perirectal lymphatic plexus
nearby the prostate, the ventrocranial parts of the internal
pudendal and inferior rectal nodes), the internal and
external iliac lymph nodes (from the bifurcation of the
common iliac lymph artery at the level of the upper sacro-
iliac joints, to the crossing point of the external iliac artery
and the inguinal ligament) and the sacral nodes anterior
Terms and definitions of nodal groups according to Martinez- Monge et al. (1999) Figure 1
Terms and definitions of nodal groups according to Martinez-
Monge et al. (1999). The obturator and hypogastric lymph 
nodes include periprostatic and seminal vesicle lymphatic 
plexus, parts of perivesical and the perirectal lymphatic 
plexus nearby the prostate, the ventrocranial parts of the 
internal pudendal and inferior rectal nodes
Internal pudendal nodes
Inferior rectal nodes
Periprostatic lymphatic plexus
Seminal vesicle lymphatic plexus
Perirectal lymphatic plexus
Perivesical lymphatic plexus
Sacral nodes
Internal iliac nodes
External iliac nodes
Superior rectal nodes
Common iliac nodes
Left paraaortic nodes
Right paraaortic nodesBMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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the first and second sacral segment. In addition to this reg-
ular second-order CTV all detected sentinel node localisa-
tions were outlined separately and involved into the IMRT
target volume definition.
Dose prescriptions were 50.4 Gy (5 × 1.8 Gy / week) to the
pelvic nodes and 70.0 Gy (5 × 2.0 Gy / week) to the pros-
tate and the base of seminal vesicles or whole seminal ves-
icles by an integrated boost planning. After forward
decision regarding gantry angles, an inverse treatment
planning was carried out by the Hyperion® software pack-
age (University of Tübingen, Germany) [30]. Based on a
class solution, six IMRT fields were used for the initial 28
fractions and 5 fields for the ensuing 7 fractions. The fol-
lowing normal tissue constraints were chosen: Rectum,
58–65 Gy serial dose constraint; Bladder, 50–56 Gy serial
dose constraint; Small Bowel, 20–22 Gy mean dose con-
straint and 50–54 Gy maximum dose constraint. The
dosimetrics were calculated by Monte Carlo dose
calculation.
Plans were produced for a 15 MV linear accelerator (Elekta
Oncology Systems®, Crawley, UK) for delivery with a mul-
tileaf collimator system using a step and shoot technique.
The IMRT plans were compared with 3D-CRT plans (four-
field-technique, gantry angles 0°, 90°, 180°, 270°) using
the Pinnacle® treatment planning system based on the
identical CTV. Dose volume histograms (DVH) were cal-
culated for each plan. The PTV dose ranges were calculated
with the minimum PTV dose defined as dose received by
≥ 99% of the PTV and the maximum dose defined as the
dose received by = 1% of the PTV. The volume percentages
Patients characteristics Figure 2
Patients characteristics.
Pat.
No.
Age cTNM-Stage Initial PSA
ng/ml
Gleason Score
(biopsies)
Risk
profile
Hormonal ablation
1 69 T1cN0M0 12.7 3+5 high GnRH-Analogon
neoadjuvant/concurrent
2 70 T1cN0M0 15.6 3+4 high
GnRH-Analogon
neoadjuvant/concurrent/
adjuvant
3 69 T3bN0M0 4.5 4+3 high
GnRH-Analogon
neoadjuvant/concurrent/
adjuvant
4 54 T3aN0M0 22.7 3+4 high
Bicalutamid+GnRH-Analogon
neoadjuvant/concurrent/
adjuvant
5 72 T2cN0M0 20.1 3+5 high
Bicalutamid+GnRH-Analogon
neoadjuvant/concurrent/
adjuvant
6 67 T2aN0M0 22.6 3+4 high
Bicalutamid+GnRH-Analogon
neoadjuvant/concurrent/
adjuvantBMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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of small bowel, large bowel (sigmoid/colon), rectum and
bladder irradiated with 63 Gy, 56 Gy, 35 Gy, 14 Gy were
recorded for each technique. The DVH comparisons were
done for each patient using the summarised plan.
Verification
Prior to each radiation fraction, the isocenter was verified
by portal imaging from 0° and 90° gantry angle. An error
of more than 2 mm was corrected. The administered
monitor units needed for one daily verification were
included in the initial dose calculation.
Analysis of toxicity
Acute gastrointestinal, genitourinary and skin toxicities
(RTOG criteria) were documented by standard forms
weekly during RT and at least after three months.
Results
Patients
Since August 2003, six patients with T1c-3b high risk pros-
tate cancers (figure 2) were evaluated. No patient had
undergone a staging lymphadenectomy of the pelvic
lymph nodes before. All patients had normal pre-thera-
peutic diagnostic findings with a clinical N0 M0 stage. All
patients received neoadjuvant and concurrent hormonal
ablation, which was recommended to continue adju-
vantly for three years. In all cases neoadjuvant treatment
had been started before the first visit in hospital.
Localisation of sentinel nodes
The transrectal intraprostatic injection of 99mTc-Nanocoll
was performed in all patients without any complications.
After radioisotope injection and image fusion, each
patient had detectable sentinel lymph nodes. The number
per patient ranged from two to nine detected lymph
nodes. Altogether, a total of twenty-nine lymph nodes
could be identified for all six patients (figure 3). The most
common localisations of identified lymph nodes were
external iliac (9), followed by internal iliac (6) and
perirectal lymphatic plexus (6). Further localisations were
common iliac (2), sacral (2), internal pudendal (1), sem-
inal vesicle lymphatic plexus (1), superior rectal (1) and
left paraaortic (1).
IMRT treatment planning
The first two patients were planned and treated in supine
position. Since prone position in combination with a
belly board allowed easier sparing of small bowel [31], we
changed to the prone position for the following four
patients. All detected sentinel lymph nodes could be
included into the second-order CTV. The IMRT plans car-
ried out by Hyperion® produced an average of 55 segments
Number and localisation of sentinel nodes Figure 3
Number and localisation of sentinel nodes. Localisation of lymph node areas not covered by a standard target volume definition 
plan are shaded grey (geographical misses).
Pat.
No.
internal
pudendal
sacral perirectal seminal vesicle
lymphatic plexus
internal
iliac
external
iliac
common
iliac
superior
rectal
left
paraaortic
total
1- - 1 -1 4 - - - 6
2- - 1 -1 - 1 1 -4
3 --- 1 1 1-- - 3
4 1 1 1 2 - ---- - 5
5- - - - 2 - - - 2
6- - 2 -3 2 1- 1 9
total 1 1 1 6 16 9 2 1 1 29BMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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(total/fraction) and 495 Monitor Units (total/fraction) for
the first 28 fractions and an average of 35 segments (total/
fraction) and 346 Monitor Units (total/fraction) for the
ensuing 7 fractions. Thus, fast delivery and practical treat-
ment times were possible. A class solution delivered stable
and comparable results for all patients. Detailed charac-
teristics of IMRT technique are shown in figure 4.
The minimum PTV dose ranged from 40 to 48.1 Gy for the
second-order PTV, including the pelvic nodes. The maxi-
mum PTV dose ranged from 72.4 to 74.2 Gy for the
prostate gland (figure 5). The critical dose of 60 Gy to the
whole bladder volume was not reached in any patient.
A critical dose to the small bowel of 50 Gy was reached in
two patients in very small volumes (0.5% and 1%, respec-
tively). Large bowel doses ≥ 5 0  G y  w e r e  s e e n  i n  v e r y
limited volumes (0%, 2.7%, 2.7%, 4.1%, 6.6% and
13.6%). The single event of a higher dose volume of
13.6% was seen in one patient (No. 5) with an adherent
sigmoid loop in close vicinity to the prostate. Rectum vol-
umes irradiated with more than 56 Gy ranged from 16.3%
to 52.1%, with more than 63 Gy from 9.5% to 36.6%. The
detailed analysis of irradiated organs at risk volume per-
centages is given in table 6.
IMRT planning results: 28 fractions including pelvic nodes with integrated boost (upper table) and 7 fractions without pelvic  nodes (lower table) Figure 4
IMRT planning results: 28 fractions including pelvic nodes with integrated boost (upper table) and 7 fractions without pelvic 
nodes (lower table). MU total / fraction adds up MU's per field and fraction (rounded), including additionally 3 MU's necessary 
for daily verification (not included in 'MU's per field and fraction)
Pat.
No.
Position Number
of fields
Gantry angles Segment
number / field
Segments
total
Monitor Units (MU)
per field and fraction
MU
average / beam
MU total /
fraction
1 supine 5 72,124,180,236,288 10,8,12,9,6 45 70,57,112,62,49 70 352
2 supine 5 72,124,180,236,288 9,12,13,9,9 52 113,128,108,102,105 111 559
3 prone 5 0,56,108,252,304 14,10,10,10,11 55 136,73,69,94,70 88 444
4 prone 6 0,56,108,180,252,304 7,11,10,12,7,15 62 82,81,126,111,82,150 105 634
5 prone 6 0,56,108,180,252,304 7,9,8,10,8,10 52 62,79,61,106,74,67 75 453
6 prone 6 0,56,108,180,252,304 12,14,9,8,10,10 63 98,109,80,69,88,82 88 528
Pat.
No.
Position Number
of fields
Gantry angles Segment
number / field
Segments
total
Monitor Units (MU)
per field and fraction
MU
average / beam
MU
total / fraction
1 supine 5 0,72,144,216,288 10,6,6,7,6 35 103,84,62,57,80 77 388
2 supine 5 0,72,144,236,288 4,6,6,5,4 25 55,77,52,49,56 58 291
3 prone 5 36,108,180,252,324 7,9,7,8,5 36 54,85,76,70,42 65 330
4 prone 5 36,108,180,252,324 11,11,10,11,11 54 80,85,83,101,79 86 432
5 prone 5 36,108,180,252,324 6,5,7,8,5 31 38,69,62,89,40 60 300
6 prone 5 36,108,180,252,324 5,6,9,5,5 30 52,74,83,67,59 69 337BMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
Page 7 of 13
(page number not for citation purposes)
Influence of sentinel node localisation on target volume 
definition
4 of 6 patients had sentinel node localisations (total 10 of
29 sentinel lymph nodes) that would not have been
treated adequately with conventional target volume defi-
nition ('geographical miss'). Thus, the target volume defi-
nition was modified by sentinel lymph node information
in 4 of 6 patients. The results of numbers and localisations
of sentinel lymph nodes are shown in table 3, grey shaded
fields show the number and localisation of geographical
misses.
The lymph node area associated with the highest proba-
bility of a 'geographical miss' was the perirectal lymph
node group with 6 identified sentinel nodes partly
localised nearby the dorsal circumference of the rectal
wall. Single sentinel nodes were found in the internal
pudendal, sacral, superior rectal and left paraaortic region.
PTV dose ranges 3D-CRT vs. IMRT Figure 5
PTV dose ranges 3D-CRT vs. IMRT. Minimum PTV dose defined as the dose received by = 99% of the PTV, maximum PTV 
dose defined as the dose received by = 1% of the PTV. * Dose contribution by the boost RT.
Pat.
No.
Treatment
planning
PTV min.
1
st order volume
(Gy)
PTV min.
2
nd order volume
(Gy)
PTV max.
1
st order volume
(Gy)
PTV max.*
2
nd order volume
(Gy)
1 3D-CRT
IMRT
67.4
67
48.3
48.1
71.8
72.9
71
70
2 3D-CRT
IMRT
68.9
63
49
42.3
71.5
74.2
70.5
70
3 3D-CRT
IMRT
67.9
65.3
47
43.7
72.6
72.5
71.2
69.5
4 3D-CRT
IMRT
67.9
62.4
49.4
40
72.2
72.4
71
70.2
5 3D-CRT
IMRT
68
65.6
49.2
45.5
71.7
72.8
70.5
70
6 3D-CRT
IMRT
68
66.4
47.9
47.7
71.9
72.5
71
68.6BMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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None of those was covered by standardised planning tar-
get volumes. The identified sentinel lymph node in the
left paraaortic area was localised at the L4/5 interspace.
Because the CT scans showed a lymph node of 11 mm
diameter at this localisation, we decided to include it.
DVH comparison between IMRT and 3D-CRT treatment 
planning
The patients were treated using IMRT technique (figure 4).
Additionally, a 3D-conformal treatment planning with a
four-field-technique (gantry angles 0°, 90°, 180°, 270°)
was produced for each patient based on the identical CT
datasets with the identical outlined CTV and OAR.
The comparison of minimum and maximum PTV doses
between 3D-CRT and IMRT is shown in figure 5. IMRT
minimum PTV dose ranged from 40 to 48.1 Gy, 3D-CRT
minimum PTV dose from 47 to 49.3 Gy for the 2nd order
PTV. IMRT minimum PTV dose ranged from 62.4 to 67
Gy, 3D-CRT minimum PTV dose from 67.4 to 68.9 Gy for
the 1st order PTV. IMRT maximum PTV dose ranged from
72.4 to 74.2 Gy, 3D-CRT maximum PTV dose from 71.5
to 72.6 Gy for the 1st order PTV.
The DVH comparisons between IMRT and 3D-CRT in
regard to small bowel, large bowel and rectum are shown
in figure 6. Small bowel volumes irradiated with 14Gy
and 35 Gy increased in four patients (in part very slightly)
by using IMRT and decreased clearly in two patients with
3D-CRT vs. IMRT Figure 6
3D-CRT vs. IMRT. – DVH comparison of small bowel, large bowel and rectum. V63Gy, V56Gy, V50Gy, V35Gy, V14Gy denote 
the volume of a given organ (in %) irradiated with 63 Gy, 56 Gy, 50 Gy, 35 Gy, 14 Gy.
Small bowel Large bowel (Sigma/Colon) Rectum
Pat.
No.
Treatment
planning
V63
Gy
V56
Gy
V50
Gy
V35
Gy
V14
Gy
V63
Gy
V56
Gy
V50
Gy
V35
Gy
V14
Gy
V63
Gy
V56
Gy
V35
Gy
V14
Gy
1 3D-CRT
IMRT
0
0
0
0
2
0
5.8
7.1
33.2
37.6
1
0
3.7
0
16.9
2.7
19
18.6
48.6
48.8
46.7
27.5
79
43.7
95.5
97
100
100
2 3D-CRT
IMRT
0
0
0
0
6.2
1
12.5
14.2
49.5
50.8
0
0
0
0
14.6
2.7
16.9
14.6
22.4
38
38.6
9.5
51.5
16.3
100
63
100
100
3 3D-CRT
IMRT
0
0
0
0
0
0.5
1.4
2.4
7.8
14.2
0
0
0
0
14.6
4.1
20.6
27.5
33.9
51.5
60.3
36.6
72.5
48.8
97.7
95.6
100
100
4 3D-CRT
IMRT
0
0
0
0
25.3
0
38
20
79
54.7
0
0
4.3
0
34
0
46.8
29
82.4
63.5
40
17
84.7
34.3
100
97.8
100
100
5 3D-CRT
IMRT
0
0
0
0
5.7
0
13.2
2.9
26.8
19.3
4.3
3
7.5
5.3
35
13.6
39.3
41.8
46.8
50
41.6
32.1
63.4
52.1
94.5
96.4
97.1
99
6 3D-CRT
IMRT
0
0
0
0
3.9
0
8.5
9.5
55.1
72.8
0.3
0
1
0
23.4
6.6
25.9
25.6
45.6
76.1
56.1
12.8
78.5
20.8
99.5
99
100
100BMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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a volume reduction in more than 10%. With IMRT the
critical dose to the small bowel of 50 Gy was seen in two
patients with volumes of 0.5% and 1%, respectively, com-
pared to 3D-CRT with five patients with volumes between
0 and 25.3%. Concerning the large bowel, IMRT similarly
caused increased low dose irradiated volumes, but signif-
icant smaller irradiated volumes at the critical dose of 50
Gy. The most important difference was seen in the irradi-
ated rectum volumes. All patients showed a clear benefit
from IMRT with a clear decrease in volumes irradiated
with 56 Gy and 63 Gy. As an example a dose distribution
of a single patient are shown in figure 7.
Acute toxicities
All patients completed the radiotherapy course after seven
weeks with a dose of 70.0 Gy without treatment interrup-
tion. During radiotherapy interval, genitourinary toxicity
RTOG Grade 1 occurred in all six patients, four patients
increased to a genitourinary toxicity RTOG Grade 2. Gas-
trointestinal toxicity RTOG Grade 1 was seen in all six
patients, two patients showed a gastrointestinal toxicity
RTOG Grade 2. No gastrointestinal or genitourinary acute
toxicity Grade 3 or 4 was noted. There were no toxicities
seen concerning the skin. All patients reported erectile
dysfunction, since neoadjuvant hormonal ablation had
been started. After three months, two patients reported
Planning example: Upper left : Sentinel lymph nodes left internal iliac (2), right internal iliac (1), perirectal on an axial SPECT  image (prone position) Figure 7
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slight genitourinary symptoms (RTOG Grade 1), one of
them had a slightly increased defecation frequency
corresponding to a gastrointestinal toxicity RTOG Grade
1. The other four patients did not show any toxicity after
three months.
Discussion
Although being still controversial, several data suggest
that an adjuvant coverage of the pelvic lymph nodes
increases the likelihood of tumour control in patients
with high risk prostate cancer. Whereas several older trials
suggested that larger irradiation portals may not increase
the treatment efficacy [32-41], recent randomised and
nonrandomised studies could demonstrate a benefit of
elective pelvic lymph node irradiation [21-23,42-47].
Of special value is the randomised four-armed RTOG 94-
13 trial, since it was designed to provide a final answer
regarding the role of adjuvant lymph node coverage. It
showed that high risk prostate cancer patients benefit
from radiotherapy of the pelvic lymph nodes combined
with neoadjuvant and concurrent hormonal ablation. A
significant benefit was documented in terms of advanced
4-year progression free survival rates [23], but not for
overall survival. Interestingly, there was no significant dif-
ference in toxicities between patients treated on any of the
four arms that may be caused by improved treatment tech-
niques in comparison to former studies. The role of pelvic
node coverage is also underlined by the fact that the
EORTC trial [21] randomised high risk and lymph node
positive patients to receive concurrent and long term
adjuvant hormonal ablation treatment or radiotherapy
alone, which included 50 Gy to the pelvis and a 20 Gy
boost to the prostate. A substantial benefit in terms of
local control, disease specific survival and overall survival
was noted for the group receiving anti-hormonal treat-
ment. Regarding 5-year clinical disease-free survival rates
of 74% and 40% (no hormonal ablation) respectively, it
has to be assumed that combined treatment with anti-
hormonal therapy and radiation of the pelvic lymph
nodes improves outcome of high risk and lymph node
positive patients. Comparable results were shown by the
RTOG 92-02 trial (including patients with cT2c-4, PSA <
150 ng/mL) combining radiotherapy of the pelvic nodes
and the prostate with anti-hormonal short vs. long term
treatment. An overall survival advantage was seen in a
subset analysis of patients with Gleason Scores 8 to 10
(81% vs. 71%) [22].
Regarding efficacy, available data make it highly likely
that the subgroup of patients with high risk of pelvic
lymph node involvement will benefit from this treatment.
Thus, it can be assumed that any further improvement in
staging and irradiation techniques will help to optimise
outcome. The sentinel concept was mainly developed for
an optimised surgical lymph node identification and dis-
section in patients with malignant melanoma [48]. This
concept can also be perfectly applied to breast cancer [49],
head & neck cancer [50] and probably also to prostate
cancer [24,25]. Key work was done by Wawroschek and
Harzmann providing evidence that 99mTc-Nanocoll based
sentinel node identification is highly sensitive and
specific. Similar results were obtained by us in a smaller
cohort [51]. Therefore, sentinel image data may be used
for radiation treatment planning.
The discussion on a potentially increased toxicity of larger
irradiation portals was mainly supported by results from
older studies, which were not based on modern CT plan-
ning. Thus, the favourable results from the RTOG 94-13
trial may in part be explained by optimised treatment
techniques. Meanwhile, few clinical studies suggest supe-
riority of IMRT when used for radiotherapy of the prostate
alone [7]. However, even less data are available concern-
ing an inclusion of the pelvic lymph nodes with IMRT.
Nutting et al. [52] performed a theoretical trial in 10
patients and compared different IMRT treatment tech-
niques among each other and to conventional 3D-CRT.
The data provided in this study show eloquently that
IMRT based irradiation protocols allow clear reduction of
limiting normal tissue exposure. In a second paper from
the same group, quality assurance aspects of clinical intro-
duction comparing a step and shoot versus dynamic arch
application were described. The authors concluded that
the technique is feasible and neither of both application
modi was superior [53]. Similarly, Mundt analysed the
applicability of an IMRT based protocol for the treatment
of pelvic lymph nodes in patients with gynaecological
malignancies [54]. The authors conclude that IMRT based
irradiation is associated with a diminished normal tissue
toxicity profile and an optimised target coverage. How-
ever, in contrast to our work, both authors used anatomi-
cally based target volume definitions rather than an
individualised sentinel lymph nodes based planning
approach.
Our approach to combine sentinel data with IMRT
addresses crucial aspects of target coverage and also toxic-
ity. To reduce the likelihood of a 'geographical miss' we
purposed the complete individualised coverage of lym-
phatic drainage using functional imaging. Possibly, indi-
vidualised target volumes may cause increased toxicities.
Not to mention, we observed a notable number of senti-
nel nodes nearby the dorsal rectal wall and their inclusion
into the target volumes causes increased toxicities when a
conventional four-field-technique is used (figure 8).
Whereas the focus of 3D treatment planning is on target
coverage, IMRT target coverage is compromised by the
need of normal tissue sparing. Our own data hint at an
optimal target volume coverage and showed a clearBMC Cancer 2005, 5:91 http://www.biomedcentral.com/1471-2407/5/91
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benefit in OAR sparing by using IMRT with low overall
acute toxicities. Thus, IMRT is necessary to decrease toxic-
ities resulting from individualised target volume
definition.
Conclusion
In order to optimise the balance between increased prob-
ability of side effects and improved target volume
coverage, we tested a sentinel node based IMRT approach.
Based on a limited number of patients the following con-
clusions can be drawn: Sentinel functional imaging opti-
mised target volume definition for IMRT is clearly feasible
with no obvious increase in acute toxicity and suitable for
larger numbers of patients. The probability of a geograph-
ical miss in target volume definition might be reduced by
an individualised target volume definition. However,
larger series are necessary to verify the expected benefit in
regard to efficacy and toxicities.
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